Mantel I, et al. - This trial entailed an assessment of the two-year outcome of aflibercept treatment for neovascular age-related macular degeneration (nAMD), with the aid of the Observe-and-Plan regimen, based on the predictability of an individual’s need for retreatment. The intent was to reduce the clinical burden. A substantial improvement was noted in the visual acuity (VA) through the Observe-and-Plan regimen. There appeared to be a requirement for fewer monitoring visits compared to other variable dosing regimens. Hence, it assisted in reducing the workload for chronic care management of nAMD.